It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The ubiquitous distribution of the classic endocannabinoid system (cannabinoid receptors CB1 and CB2) has been demonstrated within the monkey nervous system, including the retina. Transient receptor potential vanilloid type 1 (TRPV1) is a cannabinoid-like non-selective cation channel receptor that is present in the retina and binds to endovannilloids and endocannabinoids, like anandamide, 2-arachidonoylglycerol and N-arachidonoyl dopamine. Retinal expression patterns of TRPV1 are available for rodents and data in higher mammals like humans and monkeys are scarce. We therefore thoroughly examined the expression and localization of TRPV1 in the retina, at various eccentricities, of the vervet (Chlorocebus sabeus) monkey, using Western blots and immunohistochemistry. Our results demonstrate that TRPV1 is found mainly in the outer and inner plexiform layers, and in the retinal ganglion cell (RGC) layer with a higher density in the periphery. Co-immunolabeling of TRPV1 with parvalbumin, a primate horizontal cell marker, revealed a clear overlap of expression throughout the entire cell structure with most prominent staining in the cell body membrane and synaptic terminals. Furthermore, double labeling of TRPV1 and syntaxin was found throughout amacrine cells in the inner plexiform layer. Finally, double staining of TRPV1 and Brn3a allowed us to confirm its previously reported expression in the cell bodies and dendrites of RGCs. The presence of TRPV1 in the horizontal pathway suggests a function of this receptor in lateral inhibition between photoreceptors through the horizontal cells, and between bipolar cells through amacrine cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 McGill University, Departments of Psychiatry and Human Genetics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Behavioral Science Foundations, St. Kitts, Saint Kitts and Nevis (GRID:grid.14709.3b); University of Montreal, School of Optometry, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
2 University of Montreal, School of Optometry, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
3 McGill University, Departments of Psychiatry and Human Genetics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Behavioral Science Foundations, St. Kitts, Saint Kitts and Nevis (GRID:grid.14709.3b)
4 Behavioral Science Foundations, St. Kitts, Saint Kitts and Nevis (GRID:grid.14848.31); University of Montreal, School of Optometry, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); University of Southern Denmark, Department of Nuclear Medicine, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170)